Abcellera Biologics Inc ABCL

$12.70 +0.05 (0.40%)

Valuation

Market cap: 3,878,629,000
Revenue TTM: $75,130,000
Net income TTM: $-146,410,000
PE ratio: 0.00
Forward PE: —
Profit margin: -194.88%
Debt to equity: 0.00

Trading

Volume: 3,382,700
Avg volume: 6,838,356
Day's range: $12.29 – $12.93
Shares out: 306,611,000
Stochastic %K: 79%
Beta: 1.32
Analysts: Strong Sell
Price target: $16.67

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Website: https://www.abcellera.com
Address: 150 W 4th Avenue, Vancouver, Canada

Latest news

No headlines yet.

Stocktwits

erpy Sep 25, 9:40 PM

$ABCL https://www.zacks.com/stock/news/2993825/abcl-stock-surges-121-in-3-months-heres-what-you-need-to-know?cid=CS-STOCKTWITS-HL-analyst_blog|price_surge_/_plunge-2993825&adid=SYND_STOCKTWITS_HEADLINE_ANALYSTBLOG_284_2993825

0 replies

Stocktradesmoon Sep 25, 7:48 PM

$ABCL

0 replies

Stocktradesmoon Sep 25, 7:04 PM

$ABCL Last Chance 12.80’ss!! $13 Next! Largest 2026 IMS Menopause Convention Conference Next Week…we are Presenting the 12 Week Data 📊 for the EXPLOSIVE 🧨 Phase II RESULTS!!! Boom!!!! 💥 🤯 People are getting in Right NOW…Chart is PRIMED for a move $15.89-17’sss!!! So many More will be joining US after hours and buying it UP!! I wouldn’t Miss this OPPORTUNITY!!! I’m READY!!

0 replies

Stocktradesmoon Sep 25, 6:51 PM

$ABCL $13’sss next!

0 replies

Stocktradesmoon Sep 25, 6:21 PM

$ABCL 👏 Your Right! I can’t WAIT! I’m so EXCITED for the World to Learn about $ABCL Millions of People and Institutions will soon Discover what $ABCL is all About!!.. and will Watch the Results for themselves as they Present the 12 WEEK Data 📊 for an already an EXPLOSIVE 🧨 Phase II RESULTS!!! 😮 🤯 🚀 🚀 $17-20’sss next week!!

1 replies

erpy Sep 25, 6:11 PM

$ABCL Grab your shares before any fomo. Fomo isnt the time to add. Get a position your comfortable with jmho. Good luck to all. Added a few times today!!

0 replies

Stocktradesmoon Sep 25, 5:46 PM

$ABCL AbCellera has just demonstrated that its internal R&D pipeline has genuine delivery capabilities. 🔥 Successful Phase 2 clinical trial for ABCL635 🔥 Significant relief of hot flash symptoms 🔥 Secured $200 million in oversubscribed financing 🔥 Multiple pipeline programs advancing steadily 🔥 Average analyst price target around $30 The key takeaway is the company’s transformation from a pure-play antibody discovery platform into a biotech company with a substantial clinical-stage pipeline. 👀 The current momentum is compelling. EXTREMELY Bullish‼️ 🚀 $13’sss-14’sss wants it NOW!! Chart 📈 is SCREAMING it!!

1 replies

Stocktradesmoon Sep 25, 5:44 PM

$ABCL Get in Now! Or be left OUT! $13-$14’ss TODAY‼️ KNOWLEDGE is POWER! I have DONE ✅ MY Due Diligence $ABCL • Fastest company ever to deliver an antibody drug against a new viral target – COVID-19. • 14 partner-initiated molecules already in the clinic with downstream economics. • Huge partnered pipeline behind those clinical programs. • Growing internal pipeline with multiple wholly owned programs moving toward the clinic. • ABCL635 just delivered the first major clinical validation of the internal platform. • 83% reduction in hot flash frequency vs 33% placebo. • Strong balance sheet, now strengthened by another $200M. • World-class infrastructure built to discover, develop and manufacture antibodies under one roof. • Years of investment are finally moving from building the platform → producing clinical assets. • This is JUST the Beginning!!

0 replies